ArticleJournal of controlled release : official journal of the Controlled Release Society2015
Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 98 citations in OpenAlex.
- Polymeric Micelle Systems for Oral Drug Delivery of Small Molecule Therapeutics.Pharmaceutics · 2026Review
- Structure-dependent incorporation of terpenes into amphiphilic Poly(2-oxazoline) micelles.Biomedical microdevices · 2026Article
- Development of Cannabidiol-Loaded PLGA Microspheres for Long-Acting Injectable Delivery: Evaluation of Poly(2-ethyl-2-oxazoline) as an Alternative to Poly(ethylene glycol).Pharmaceutics · 2026Article
- Biological ActivityBiomacromolecules · 2023Article
- Article
- Strategies for the drug discovery and development of taxane anticancer therapeutics.Expert opinion on drug discovery · 2022Review
- PEG-Free Polyion Complex Nanocarriers for Brain-Derived Neurotrophic Factor.Pharmaceutics · 2022Article
- Preparation, Characterization, and In Vitro Anticancer Activity Evaluation of Broccoli-Derived Extracellular Vesicle-Coated Astaxanthin Nanoparticles.Molecules (Basel, Switzerland) · 2022Article
- Poly(2-oxazoline)-magnetite NanoFerrogels: Magnetic field responsive theranostic platform for cancer drug delivery and imaging.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.European journal of drug metabolism and pharmacokinetics · 2021Review
- Tuning the Thermogelation and Rheology of Poly(2-Oxazoline)/Poly(2-Oxazine)s Based Thermosensitive Hydrogels for 3D Bioprinting.Gels (Basel, Switzerland) · 2021Article
- Effect of Dexamethasone on Thermoresponsive Behavior of Poly(2-Oxazoline) Diblock Copolymers.Polymers · 2021Article
- Anti-Cancer Activity Based on the High Docetaxel Loaded Poly(2-Oxazoline)s Micelles.International journal of nanomedicine · 2021Article
- Complex Temperature and Concentration Dependent Self-Assembly of Poly(2-oxazoline) Block Copolymers.Polymers · 2020Article
- Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer.International journal of nanomedicine · 2020Article
- Antitumor Activity of Cabazitaxel and MSC-TRAIL Derived Extracellular Vesicles in Drug-Resistant Oral Squamous Cell Carcinoma.Cancer management and research · 2020Article
- Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.Advanced drug delivery reviews · 2020Review
- A Novel Paclitaxel Conjugate with Higher Efficiency and Lower Toxicity: A New Drug Candidate for Cancer Treatment.International journal of molecular sciences · 2019Article
- Ultra-High to Ultra-Low Drug-Loaded Micelles: Probing Host-Guest Interactions by Fluorescence Spectroscopy.Chemistry (Weinheim an der Bergstrasse, Germany) · 2019Article
- Novel poly(2-oxazoline) block copolymer with aromatic heterocyclic side chains as a drug delivery platform.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
The clinically and commercially successful taxanes, paclitaxel and docetaxel suffer from two major drawbacks, namely their very low aqueous solubility and the risk of developing resistance. Here, we present a method that overcomes both drawbacks in a very simple manner. We formulated 3rd generation taxoids, able to avoid common drug resistance mechanisms with doubly amphiphilic poly(2-oxazoline)s (POx), a safe and highly efficient polymer for the formulation of extremely hydrophobic drugs. We found excellent solubilization of different 3rd generation taxoids irrespective of the drug's chemical structures with essentially quantitative drug loading and final drug to polymer ratios around unity. The small, highly loaded micelles with a hydrodynamic diameter of less than 100nm are excellently suited for parenteral administration. Moreover, a selected formulation with the taxoid SB-T-1214 is about one to two orders of magnitude more active in vitro than paclitaxel in the multidrug resistant breast cancer cell line LCC6-MDR. In contrast, in wild-type LCC6, no difference was observed. Using a q4d×4 dosing regimen, we also found that POx/SB-T-1214 significantly inhibits the growth of LCC6-MDR orthotropic tumors, outperforming commercial paclitaxel drug Taxol and Cremophor EL formulated SB-T-1214.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.